German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million ...

BioNTech (BNTX) recently experienced a 10% price increase in the last quarter, coinciding with the Health Canada's authorization of its variant-adapted COMIRNATY COVID-19 vaccine, a potential positive ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

Pfizer's Canadian unit and BioNTech said they have received approval in Canada for their updated Comirnaty Covid-19 vaccine. The companies said Monday the updated vaccine targets the Omicron LP.8.1 ...

New data from the Kentucky Cabinet for Health and Family Services shows cases of the virus have jumped significantly in the ...

BioNTech SE is currently sponsoring a Phase II clinical study titled A Phase II, Multisite, Open-label, Single Arm Trial of BNT327 in Combination With Docetaxel in Second-line Stage IV Non-small Cell ...

The outcome of this study could significantly influence BioNTech’s stock performance and investor sentiment, especially if the combination therapy proves more effective than the standard treatment.

Moderna is suing fellow vaccine developers Pfizer and its German partner BioNTech, accusing it of infringing on patents related to mRNA technology used in their COVID-19 vaccine, the company ...

Moderna is suing Pfizer and its German partner BioNTech for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that ...

Pfizer and BioNTech are planning to ask the Food and Drug Administration to authorize a second COVID-19 booster shot for people age 65 and older.

Fosun, BioNTech’s Chinese partner, told investors last year that regulators would approve its mRNA vaccine for use in China by July 2021. Alex Plavevski/EPA, via Shutterstock ...